Use of one or more classes of medications for secondary CVD prevention peaked at 43.1 percent, decreased to 31.3 percent
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy PolicyOk